home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

353.93 +5.50 (+1.58%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

64 65 Next >

Check Out What Whales Are Doing With AMGN ↗

October 12, 2023

Via Benzinga

Prescriptions for Portfolio Health: 3 Resilient Healthcare Stocks

October 12, 2023

During the peak of the recent selloff, the healthcare sector outshone, with three stocks showing resilience and impressive upward moves.

Via MarketBeat

Topics ETFs

Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade ↗

October 11, 2023

The company has growing pipeline optionality, according to the upgrade report.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

October 11, 2023

Via Benzinga

Expert Ratings for Amgen ↗

October 11, 2023

Via Benzinga

Should You Still Buy the Nasdaq's Best-Performing September Stocks? ↗

October 10, 2023

Tech stocks sold off last month, but these three were gainers.

Via The Motley Fool

$100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today ↗

October 09, 2023

Via Benzinga

Check Out What Whales Are Doing With AMGN ↗

September 29, 2023

Via Benzinga

2 Dividend Growth Stocks to Buy Right Now ↗

September 21, 2023

A wise man once said, be greedy when others are fearful.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

October 09, 2023

Via Benzinga

2 Magnificent Dividend Stocks to Buy Hand Over Fist in October ↗

October 09, 2023

These two healthcare stocks are reliable passive income vehicles.

Via The Motley Fool

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid ↗

October 09, 2023

Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion.

Via Investor's Business Daily

Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts ↗

October 06, 2023

According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX).

Via Benzinga

FDA Adcomm Gives Thumbs Down To Amgen's Lumakras For Advanced Form Of Lung Cancer ↗

October 06, 2023

FDA advisers concluded that the data from a late-stage trial lacked the requisite reliability to endorse the traditional approval of Amgen Inc's (NASDAQ: AMGN) Lumakras for patients afflicted with an...

Via Benzinga

Check Out What Whales Are Doing With AMGN ↗

September 20, 2023

Via Benzinga

Amgen Unusual Options Activity ↗

September 15, 2023

Via Benzinga

Biotech Sector: On The Verge Of Triumph Or Turmoil? ↗

October 06, 2023

In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.

Via Talk Markets

Should You Still Buy the Dow Jones' Best-Performing September Stocks? ↗

October 04, 2023

A handful of blue-chip tickers defied the bigger bearish tide last month, but that doesn't necessarily make these stocks a buy.

Via The Motley Fool

Topics Stocks

Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns ↗

October 03, 2023

The FDA released briefing documents ahead of Oncologic Drugs Advisory Committee meeting scheduled for October 5 to review Amgen Inc's (NASDAQ:

Via Benzinga

Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration ↗

October 03, 2023

All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration

Via Benzinga

AskSlim Market Week - Friday, Sep. 29 ↗

September 29, 2023

Technical and cycle analysis, and market commentary.

Via Talk Markets

3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals ↗

September 28, 2023

The demand for biotech stocks is intense and is likely to only greatly increase going forward, especially in the United States.

Via InvestorPlace

September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average ↗

September 27, 2023

The September market downturn is spreading like wildfire across various sectors, with only a handful of stocks managing to maintain the positive trend seen in recent months.

Via Benzinga

Topics Stocks

FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients ↗

September 25, 2023

The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of...

Via Benzinga

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

AI To Revolutionize Clinical Trials And Diagnostics ↗

September 22, 2023

With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving...

Via Benzinga

Topics Artificial Intelligence

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

September 22, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...

Via FinancialNewsMedia

From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗

September 22, 2023

Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These...

Via Benzinga

Topics Artificial Intelligence

Why Shares of Neumora Therapeutics Slumped This Week ↗

September 21, 2023

The clinical-stage biotech just had its IPO last week.

Via The Motley Fool

Topics Initial Public Offering

Flee to Healthcare Stocks if Recession Rears its Head?

September 20, 2023

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

Via MarketBeat

Topics Economy

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com